Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 1 h ago
Peer-reviewedCC BY-NC 4.0Patient Preference and Adherence

Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies

  • Batyrkhan Kuatov1
  • Gemma Al-Jassar2
  • Katja Rudell2
  • Tommi Tervonen3
  • Anita Burrell4
  • Shicheng Weng5
  • Julia Braverman6
6 affiliations
  1. 1HEOR, Global Market Access, CSL Behring, Bern, Switzerland
  2. 2Kielo Research, York, UK
  3. 3Kielo Research, Zug, Switzerland
  4. 4Anita Burrell Consulting LLC, Flemington, NJ, USA
  5. 5Medical Affairs and HTA Statistics, CSL Behring, Waltham, MA, USA
  6. 6Patient Centered Science, CSL Behring, Waltham, MA, USA
Read full textPDFDOICite

Abstract

Batyrkhan Kuatov,1 Gemma Al-Jassar,2 Katja Rudell,2 Tommi Tervonen,3 Anita Burrell,4 Shicheng Weng,5 Julia Braverman61HEOR, Global Market Access, CSL Behring, Bern, Switzerland; 2Kielo Research, York, UK; 3Kielo Research, Zug, Switzerland; 4Anita Burrell Consulting LLC, Flemington, NJ, USA; 5Medical Affairs and HTA Statistics, CSL Behring, Waltham, MA, USA; 6Patient Centered Science, CSL Behring, Waltham, MA, USACorrespondence: Julia Braverman, Patient Centered Science, CSL Behring, 225 Wyman Street, Waltham, 02451, USA, Email [email protected]: Primary immunodeficiency (PID) patients can receive subcutaneous immunoglobulin (SCIG) therapy using vials or pre-filled syringes (PFS). This research explored patient experience in the United States (US) with both presentation forms related to adherence, satisfaction, convenience, and impacts to quality-of-life.Patients and Methods: A cross-sectional, qualitative interview study of 24 US PID patients currently administering IgPro20 PFS and who have prior experience in using vials.Results: Patient’s mean age was 54 years (median = 51, range 23– 79), 17% were male and 83% were female, and mean time since diagnosis was 16 years (median = 12, range 3– 47). Most patients (83%) reported being more satisfied with IgPro20 PFS than vials and found them more convenient (75%). Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with IgPro20 PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and IgPro20 PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to IgPro20 PFS, related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.Conclusion: Participants experienced in both SCIG presentation forms were more satisfied, reported improved convenience, and were more adherent with IgPro20 PFS compared with vials. The positive benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their quality-of-life.Keywords: IgPro20, immunoglobulin G, IgG, intravenous immunoglobulin, IVIG, pre-filled syringe, PFS, primary immunodeficiency disease, PID, subcutaneous immunoglobulin, SCIG

Related

  1. Aspergillus and Candida in primary and secondary immunodeficiencies in USIDNET
    S. Y. Starkey, USIDNET Consortium, K. E. Sullivan
    medRxivPreprintPublic domainFull textImmunologymedRxiv
  2. Development of functional assays for CD25/Interleukin-2 axis in primary immunodeficiencies
    Evangelos Tsioupros, Eleni Tsapalou, Kristina Spahiu +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  3. Experiences of palliative care for patients with pulmonary fibrosis: A qualitative exploration of patients and partners perspectives
    Lian Trapman, Lea M. Dijksman, Jan C. Grutters +2
    PLOS OnePeer-reviewedCC BY 4.0Full textDevelopmental biologyPLOS
  4. Opportunities and Challenges for Promoting Sustainable Diets within "Food is Medicine" Programs in the United States: A Qualitative Research Study.
    Katherine Consavage Stanley, Paige B Harrigan, Bailey Houghtaling +4
    Current developments in nutritionPeer-reviewedCC BYFull textEcologyEurope PMC
  5. Experiences of self-management behaviors during adaptation to permanent enterostomy among older patients: A qualitative study
    Zhichao Duan, Fang Wu
    PLOS OnePeer-reviewedCC BYFull textNeuroscienceOncologyPLOSEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{kuatov2026qualitative,
  title = {{Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies}},
  author = {Batyrkhan Kuatov and Gemma Al-Jassar and Katja Rudell and Tommi Tervonen and Anita Burrell and Shicheng Weng and Julia Braverman},
  journal = {Patient Preference and Adherence},
  year = {2026},
  month = oct,
  doi = {10.2147/ppa.s635243},
  url = {https://www.dovepress.com/qualitative-research-on-igpro20-prefilled-syringe-use-among-us-patient-peer-reviewed-fulltext-article-PPA},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies
AU  - Batyrkhan Kuatov
AU  - Gemma Al-Jassar
AU  - Katja Rudell
AU  - Tommi Tervonen
AU  - Anita Burrell
AU  - Shicheng Weng
AU  - Julia Braverman
PY  - 2026
DA  - 2026/10/01
JO  - Patient Preference and Adherence
DO  - 10.2147/ppa.s635243
UR  - https://www.dovepress.com/qualitative-research-on-igpro20-prefilled-syringe-use-among-us-patient-peer-reviewed-fulltext-article-PPA
AB  - Batyrkhan Kuatov,1 Gemma Al-Jassar,2 Katja Rudell,2 Tommi Tervonen,3 Anita Burrell,4 Shicheng Weng,5 Julia Braverman61HEOR, Global Market Access, CSL Behring, Bern, Switzerland; 2Kielo Research, York, UK; 3Kielo Research, Zug, Switzerland; 4Anita Burrell Consulting LLC, Flemington, NJ, USA; 5Medical Affairs and HTA Statistics, CSL Behring, Waltham, MA, USA; 6Patient Centered Science, CSL Behring, Waltham, MA, USACorrespondence: Julia Braverman, Patient Centered Science, CSL Behring, 225 Wyman Street, Waltham, 02451, USA, Email [email protected]: Primary immunodeficiency (PID) patients can receive subcutaneous immunoglobulin (SCIG) therapy using vials or pre-filled syringes (PFS). This research explored patient experience in the United States (US) with both presentation forms related to adherence, satisfaction, convenience, and impacts to quality-of-life.Patients and Methods: A cross-sectional, qualitative interview study of 24 US PID patients currently administering IgPro20 PFS and who have prior experience in using vials.Results: Patient’s mean age was 54 years (median = 51, range 23– 79), 17% were male and 83% were female, and mean time since diagnosis was 16 years (median = 12, range 3– 47). Most patients (83%) reported being more satisfied with IgPro20 PFS than vials and found them more convenient (75%). Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with IgPro20 PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and IgPro20 PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to IgPro20 PFS, related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.Conclusion: Participants experienced in both SCIG presentation forms were more satisfied, reported improved convenience, and were more adherent with IgPro20 PFS compared with vials. The positive benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their quality-of-life.Keywords: IgPro20, immunoglobulin G, IgG, intravenous immunoglobulin, IVIG, pre-filled syringe, PFS, primary immunodeficiency disease, PID, subcutaneous immunoglobulin, SCIG
SN  - 1177-889X
ER  -